EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications

Angel T Alvarado, Amparo Iris Zavaleta, César Li-Amenero, María R Bendezú, Jorge A Garcia, Haydee Chávez, Juan J Palomino-Jhong, Felipe Surco-Laos, Doris Laos-Anchante, Elizabeth J Melgar-Merino, Pompeyo A Cuba-Garcia, Paulina E Yarasca-Carlos

Frontiers in Pharmacology · 12.08.2025 · 16

DOI: 10.3389/fphar.2025.1640401 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.08.2025. Verfasst von Angel T Alvarado und 11 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit in Molecular Pharmacology and 4P Medicine, VRI, San Ignacio de Loyola University, Lima, Peru. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epilepsy is the second most common neurological condition worldwide, characterized by recurrent, unprovoked, self-limiting seizures of genetic, acquired, or unknown origin. The objective was to describe the pharmacogenomic markers associated with hypersensitivity reactions induced by aromatic antiseizure medications. This review explored the pharmacokinetics, pharmacogenomics of CYP2C9 and HLA associated with hypersensitivity reactions, immunopathogenesis and its clinical implications. The included studies applied odds ratio (OR), 95% confidence interval (95% CI) and p value, as association statistics between severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). An association study was found between CYP2C19*2 and SCARs induced by carbamazepine, phenytoin and phenobarbital. Five studies of CYP2C9*3 associated with phenytoin-induced SCARs, four studies of CYP2C9*3 , HLA-B*13:01 , HLA-B*15:02 , HLA-B*51:01 and HLA-B*55:01 HLA-B*46:01 and HLA-B*56:02/04 associated with phenytoin-induced SCARs. Likewise, six studies found an association between HLA-B*15:02 and carbamazepine-induced SJS/TEN, four studies associated HLA-A*02:07 , HLA-A*24:02 , HLA-A*33:03 , HLA-B*15:02 , HLA-B*44:03 with lamotrigine-induced SCARs, one study associated HLA-A*02:01 , HLA-B*35:01 , HLA-C*04:01 , and HLA-C*08:01 with lamotrigine- and phenytoin-induced SCARs. Three association studies between HLA-A*02:01 , HLA-A*11:01 , HLA-A*24:02 , HLA-B*15:02 , HLA-B*38:01 , HLA-B*40:02 and HLA-DRB1*03:01 with SCARs induced by carbamazepine, lamotrigine and phenytoin. Published scientific evidence demonstrates that CYP2C9*3 and various HLA alleles are associated with severe cutaneous adverse reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome. Neurologists should consider these allelic variants as predictive and preventive genetic biomarkers of severe adverse reactions to carbamazepine, phenytoin, phenobarbital, and lamotrigine, especially in Asian populations.

Schlagwörter

Stichwörter der Autor:innen

antiseizure medicationsclinical implicationsepilepsyhypersensitivity reactionspharmacogenomics

Autor:innen und Institutionen

  • Research Unit in Molecular Pharmacology and 4P Medicine, VRI, San Ignacio de Loyola University, Lima, Peru.
  • Molecular Biology Laboratory, Faculty of Pharmacy and Biochemistry, National University of San Marcos, Lima, Peru.
  • Victor Larco Herrera Hospital, Lima, Peru.
  • Faculty of Pharmacy and Biochemistry, San Luis Gonzaga National University of Ica, Ica, Peru.
  • Biological Sciences Faculty, San Luis Gonzaga National University of Ica, Ica, Peru.

Zitieren

APA

Alvarado, A. T., Zavaleta, A. I., Li-Amenero, C., Bendezú, M. R., Garcia, J. A., Chávez, H., Palomino-Jhong, J. J., Surco-Laos, F., Laos-Anchante, D., Melgar-Merino, E. J., Cuba-Garcia, P. A., & Yarasca-Carlos, P. E. (2025). Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1640401

Vancouver

Alvarado AT, Zavaleta AI, Li-Amenero C, Bendezú MR, Garcia JA, Chávez H, et al. Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1640401

BibTeX
@article{Alvarado2025,
  author = {Alvarado, Angel T and Zavaleta, Amparo Iris and Li-Amenero, César and Bendezú, María R and Garcia, Jorge A and Chávez, Haydee and Palomino-Jhong, Juan J and Surco-Laos, Felipe and Laos-Anchante, Doris and Melgar-Merino, Elizabeth J and Cuba-Garcia, Pompeyo A and Yarasca-Carlos, Paulina E},
  title = {Role of pharmacogenomics for prevention of hypersensitivity reactions induced by aromatic antiseizure medications},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1640401}
}
Kostenlos starten →